Over the past few decades there has been a dramatic decline in domestic production of active pharmaceutical ingredients (APIs), raising important questions about patient safety, national security, drug availability, vulnerability, and quality. These concerns have only grown since the COVID-19 pandemic. This webinar will cover the roots and consequences of declining domestic API and finished dosage manufacturing on the drug supply chain, regulatory options for improving the quality of foreign-produced APIs and/or increasing domestic API production, and what changes can be made by companies, FDA, or Congress to strengthen the drug supply chain.

Get Access

  • +$100 for nonmembers

Internet Explorer and Microsoft Edge are not supported by the checkout process.

Please use Chrome, Firefox, or Safari.  If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.


Jeffrey K. Francer, Senior Vice President and General Counsel, Association for Accessible Medicines (AAM) and Member, FDLI Board of Directors
Michael Ganio, Senior Director, Pharmacy Practice and Quality, Center on Medical Safety and Quality, American Society of Health-System Pharmacists (ASHP)
Ronald T. Piervincenzi, CEO, US Pharmacopeia
Anand Shah, Deputy Commissioner for Medical and Scientific Affairs, FDA
Moderated by Beth P. Weinman, Counsel, Ropes & Gray LLP

Virtual Learning FAQ

On-demand webinar content is sent via email as soon as we are able to process and verify your order. This usually occurs within 1 business day.


On-demand content can be played back on most devices.


CLE credit is not currently available for pre-recorded sessions.

Related Content